The Board of NorthX Biologics has appointed the former Director General of SwedenBIO, Helena Strigård, as their new Chief Executive Officer.
She will lead NorthX’s continued expansion in the development and production of advanced biologics. Ted Fjällman, current CEO of NorthX and Partner of the company’s main investor, Flerie Invest, will continue to support the company as a member of the board.
“I am excited to be joining at this stage in the company’s growth and will use all my industry know-how and global network to ensure that we succeed.”
“NorthX has in a short time built up a broad capacity for advanced biologics. I am excited to be joining at this stage in the company’s growth and will use all my industry know-how and global network to ensure that we succeed,” commented Helena Strigård in the company’s press release.
Achieve international impact
Helena Strigård has broad experience from the Ministry of Finance and Vinnova and has taken the organization SwedenBIO through a period of rapid expansion, which saw the membership income doubled, stated NorthX Biologics in its press release.
“Under Helena’s leadership, SwedenBIO has taken its place on international arenas to the benefit of the entire industry. NorthX will be able to leverage that driving force to achieve international impact. As a Board we look forward to working with her in order to achieve this important goal,” commented Thomas Eldered, chairman of the board of NorthX.
Strigård takes up her role on the 6th October.
Photo of Helena Strigård: NorthX Biologics